🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are increasing worldwide, with figures suggesting more than 82 million new cases per year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the face of growing infection rates, the spread of superbugs and the highly restricted treatment choices presently on offer.”

Health officials are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is additionally indicated for urinary tract infections, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to see it through.

“This milestone marks a significant shift in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Results and Global Access

Based on results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which uses an injection and a pill. The research included nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the ability to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals directly involved have shared optimism. The availability of a single-dose, oral treatment such as this is seen as a "critical tool" for managing the epidemic. This is considered vital to reduce the burden of the infection for people and to halt the transmission of untreatable gonorrhoea worldwide.